Pathogen-reduced cryoprecipitate: Early experiences and inventory management.

Area of Science:

• Transfusion Medicine
• Hematology
• Clinical Pathology

Background:

• Cryoprecipitated antihemophilic factor (CryoAHF) requires frozen storage and thawing, delaying fibrinogen supplementation.
• Pathogen-reduced cryoprecipitated fibrinogen complex (PRCFC) offers room temperature storage for up to 5 days, enabling rapid dispensing.
• PRCFC presents an opportunity to decrease product wastage and improve efficiency in transfusion services.

Purpose of the Study:

• To evaluate the implementation of PRCFC in a clinical setting.
• To compare the turnaround time (TAT) for issuing PRCFC versus CryoAHF.
• To assess the impact of PRCFC on cryoprecipitate wastage.

Main Methods:

• Retrospective analysis of order data between January 2022 and December 2024.
• PRCFC was maintained thawed at room temperature for rapid dispensing.
• Exclusion of orders with TAT exceeding 60 minutes to focus on urgent or standard use.

Main Results:

• PRCFC accounted for 40.3% of cryoprecipitate orders.
• Significant TAT reductions observed for PRCFC compared to CryoAHF in critical care areas (up to 50.0% decrease).
• A 54.2% reduction in cryoprecipitate wastage was achieved with PRCFC implementation.

Conclusions:

• PRCFC provides an immediately available fibrinogen source, significantly reducing TAT for critically bleeding patients.
• The use of PRCFC enhances efficiency in transfusion services and reduces product wastage.
• PRCFC implementation offers substantial clinical and operational benefits in managing fibrinogen replacement therapy.